Gland Pharma (GLAND.BO) Earnings Analysis
Gland Pharma (GLAND.BO) next reports earnings on 2026-08-11, consensus EPS 18.01 INR. Last quarter (2026-05-15) it beat with EPS 22.3 INR vs 16.25 INR est (+37.2%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E 38.20.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GLAND.BO next report earnings?
| Next earnings date | 2026-08-11 |
|---|---|
| Consensus EPS estimate | 18.01 INR |
| Revenue estimate | 17.43B |
GLAND.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-15 | 22.3 INR | 16.25 INR | +37.2% | Beat |
| 2026-01-27 | 15.87 INR | 15.37 INR | +3.3% | Beat |
| 2025-11-03 | 11.15 INR | 16.26 INR | -31.4% | Miss |
| 2025-05-20 | 11.3 INR | 12.51 INR | -9.7% | Miss |
| 2025-02-03 | 12.4 INR | 12.47 INR | -0.6% | Miss |
| 2024-11-04 | 9.93 INR | 10.76 INR | -7.7% | Miss |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
GLAND.BO valuation and analyst view
| Trailing P/E | 38.20 |
|---|---|
| Trailing EPS | 62.366 INR |
| Price / book | 3.79 |
| Dividend yield | 1.60% |
| Market cap | 402.23B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Gland Pharma (GLAND.BO)'s next earnings date?
Gland Pharma is next scheduled to report on 2026-08-11, with a consensus EPS estimate of 18.01 INR and revenue estimate of 17.43B.
Did GLAND.BO beat earnings last quarter?
In its 2026-05-15 report, GLAND.BO posted EPS of 22.3 INR versus a 16.25 INR estimate — a beat of 37.2%.
What is GLAND.BO's earnings track record?
Over the last 6 reported quarters with consensus data, GLAND.BO beat estimates 2 times (33%).
What is GLAND.BO's current P/E ratio and EPS?
GLAND.BO trades at a trailing P/E of 38.20 on trailing EPS of 62.365896894198784 INR.
What do analysts rate GLAND.BO?
GLAND.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.